Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310235280> ?p ?o ?g. }
- W4310235280 endingPage "1167" @default.
- W4310235280 startingPage "1151" @default.
- W4310235280 abstract "Introduction Since the approval of sorafenib for systemic treatment of advanced hepatocellular carcinoma (HCC), many tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have shown efficacy and tolerability as first-line treatments. On the other hand, these first-line therapies are associated with low objective response and drug resistance. Many drugs have been successfully tested for second-line treatment of advanced HCC. While the rapid proliferation of second-line treatments for advanced HCC brings hope to patients, it also complicates clinical decision-making.Areas covered This review aims to facilitate decisions by summarizing the latest guidelines for second-line treatment of HCC in various countries or regions. We then review existing second-line treatment options and discuss challenges that should be addressed in the future. A literature search was conducted in April 2022 of PubMed/Medline, Cochrane library, and abstracts of international cancer meetings.Expert opinion There is no standard second-line treatment, especially for the case of sequential treatment after atezolizumab plus bevacizumab (atezo+bev) and further studies focused on sequential treatment are warranted in this setting. The design of clinical trials, different etiologies, and complications or quality of life (QoL) are interesting issues in the second-line setting." @default.
- W4310235280 created "2022-11-30" @default.
- W4310235280 creator A5012809258 @default.
- W4310235280 creator A5035766727 @default.
- W4310235280 creator A5035908102 @default.
- W4310235280 creator A5045745571 @default.
- W4310235280 creator A5047651229 @default.
- W4310235280 creator A5048945818 @default.
- W4310235280 creator A5050984282 @default.
- W4310235280 creator A5052670979 @default.
- W4310235280 date "2022-11-02" @default.
- W4310235280 modified "2023-10-18" @default.
- W4310235280 title "Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future" @default.
- W4310235280 cites W1536480181 @default.
- W4310235280 cites W1828082159 @default.
- W4310235280 cites W1914776013 @default.
- W4310235280 cites W1964991674 @default.
- W4310235280 cites W1971837077 @default.
- W4310235280 cites W1994193851 @default.
- W4310235280 cites W2013043293 @default.
- W4310235280 cites W2019557476 @default.
- W4310235280 cites W2031472841 @default.
- W4310235280 cites W2052730188 @default.
- W4310235280 cites W2080762633 @default.
- W4310235280 cites W2110647409 @default.
- W4310235280 cites W2153297361 @default.
- W4310235280 cites W2277004004 @default.
- W4310235280 cites W2308363199 @default.
- W4310235280 cites W2560499218 @default.
- W4310235280 cites W2582878252 @default.
- W4310235280 cites W2590716867 @default.
- W4310235280 cites W2592522896 @default.
- W4310235280 cites W2606367731 @default.
- W4310235280 cites W2617206715 @default.
- W4310235280 cites W2625559053 @default.
- W4310235280 cites W2626033245 @default.
- W4310235280 cites W2664203916 @default.
- W4310235280 cites W2730190317 @default.
- W4310235280 cites W2754081264 @default.
- W4310235280 cites W2754454631 @default.
- W4310235280 cites W2759382352 @default.
- W4310235280 cites W2765836977 @default.
- W4310235280 cites W2786264829 @default.
- W4310235280 cites W2787358630 @default.
- W4310235280 cites W2789258259 @default.
- W4310235280 cites W2791328450 @default.
- W4310235280 cites W2795488377 @default.
- W4310235280 cites W2796207838 @default.
- W4310235280 cites W2797410539 @default.
- W4310235280 cites W2799933121 @default.
- W4310235280 cites W2801111216 @default.
- W4310235280 cites W2803002566 @default.
- W4310235280 cites W2805592007 @default.
- W4310235280 cites W2806839461 @default.
- W4310235280 cites W2809889937 @default.
- W4310235280 cites W2810905077 @default.
- W4310235280 cites W2883204623 @default.
- W4310235280 cites W2887577080 @default.
- W4310235280 cites W2888259312 @default.
- W4310235280 cites W2890100090 @default.
- W4310235280 cites W2890487472 @default.
- W4310235280 cites W2897612290 @default.
- W4310235280 cites W2898112292 @default.
- W4310235280 cites W2908573150 @default.
- W4310235280 cites W2914486061 @default.
- W4310235280 cites W2915650040 @default.
- W4310235280 cites W2933348020 @default.
- W4310235280 cites W2945590213 @default.
- W4310235280 cites W2945730831 @default.
- W4310235280 cites W2947216792 @default.
- W4310235280 cites W2966565435 @default.
- W4310235280 cites W2977722669 @default.
- W4310235280 cites W2989703635 @default.
- W4310235280 cites W2990602950 @default.
- W4310235280 cites W2995341450 @default.
- W4310235280 cites W2995953853 @default.
- W4310235280 cites W3008514541 @default.
- W4310235280 cites W3025022288 @default.
- W4310235280 cites W3026099517 @default.
- W4310235280 cites W3026296708 @default.
- W4310235280 cites W3031070321 @default.
- W4310235280 cites W3034803562 @default.
- W4310235280 cites W3036157555 @default.
- W4310235280 cites W3040740064 @default.
- W4310235280 cites W3045387409 @default.
- W4310235280 cites W3046180289 @default.
- W4310235280 cites W3049075450 @default.
- W4310235280 cites W3080424252 @default.
- W4310235280 cites W3081945916 @default.
- W4310235280 cites W3089762019 @default.
- W4310235280 cites W3090413519 @default.
- W4310235280 cites W3093964219 @default.
- W4310235280 cites W3094496272 @default.
- W4310235280 cites W3099108820 @default.
- W4310235280 cites W3100629716 @default.
- W4310235280 cites W3106195099 @default.
- W4310235280 cites W3108891610 @default.
- W4310235280 cites W3111244361 @default.